Clinical trials using targeted therapy with antibodies against HER2 have revealed poor responses in patients [58,59], which could be attributed to weaker overall HER2 expression in ovarian cancer than in HER2-positive breast cancer. This evidence concerns the gene ERBB2 and breast cancer.